Literature DB >> 9741925

A new non-viral DNA delivery vector: the terplex system.

J S Kim1, B I Kim, A Maruyama, T Akaike, S W Kim.   

Abstract

A new DNA delivery vector (the terplex system) based on a balanced hydrophobicity and net surface charge between stearyl-poly(L-lysine), low density lipoprotein (LDL), and genetic material (i.e. plasmid DNA or antisense oligonucleotide) was developed. The pSV-beta-gal plasmid in terplex system showed a 2-5-fold increase in beta-galactosidase expression on murine smooth muscle cells (A7R5) compared to Lipofectin. Delivery of unmodified c-myb antisense oligonucleotide to A7R5 cells was also facilitated significantly by the terplex system, requiring as little as 5.4 nM of antisense oligonucleotide to achieve a 50% antiproliferative effect. Similar antiproliferative effect was observed when the c-myb antisense/terplex formulation was tested on CCD-32 Lu human lung fibroblasts. Characterization of the physical properties of the terplex system was performed using various techniques. Plasmid DNA was condensed by addition of stearyl-PLL and LDL, resulting in the terplex system of about 100 nm in diameter as shown by atomic force microscopy. A strong hydrophobic interaction between stearyl-poly(L-lysine) and LDL was registered by 1H-NMR spectrometry, showing a significant decrease in the epsilon-methylene signal of poly(L-lysine) backbone when stearyl-poly(L-lysine) was mixed with LDL; however, this phenomenon was not observed with unmodified poly(L-lysine). Agarose gel electrophoresis revealed that electrophoretic mobility of the terplex system decreased with increasing amounts of stearyl-poly(L-lysine), indicating that the surface charge of the terplex system became more positive by addition of stearyl-poly(L-lysine). Zeta-potential measurement showed that the terplex system exerted a slightly positive charge (+2 mV) at a 1:1:1 weight ratio of plasmid DNA:LDL:stearyl-poly(L-lysine). The obtained results will be utilized in the design of more efficient and safer DNA delivery vectors for in vivo gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741925     DOI: 10.1016/s0168-3659(97)00251-4

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  16 in total

1.  Long term stability of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems.

Authors:  J Y Cherng; H Talsma; D J Crommelin; W E Hennink
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Systemic administration of TerplexDNA system: pharmacokinetics and gene expression.

Authors:  L Yu; H Suh; J J Koh; S W Kim
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

3.  In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system.

Authors:  Guangliang Pan; Mohannad Shawer; Svein Oie; D Robert Lu
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

Review 4.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 5.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 6.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

Review 7.  Non-viral nucleic acid containing nanoparticles as cancer therapeutics.

Authors:  Kristen L Kozielski; Yuan Rui; Jordan J Green
Journal:  Expert Opin Drug Deliv       Date:  2016-06-06       Impact factor: 6.648

8.  PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy.

Authors:  Jihoon Kim; Sung Wan Kim; Won Jong Kim
Journal:  Oligonucleotides       Date:  2011-03-04

9.  Biomaterials to gene delivery.

Authors:  Sung Wan Kim
Journal:  J Control Release       Date:  2011-03-30       Impact factor: 9.776

Review 10.  Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.

Authors:  James W Yockman; Sung Wan Kim; David A Bull
Journal:  Adv Drug Deliv Rev       Date:  2009-05-05       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.